MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs.
Since its foundation in 1999, MMV and partners have developed and brought forward seven new medicines: Coartem® Dispersible (artemether-lumefantrine), a child-friendly formulation developed with Novartis; Guilin’s artesunate injection Artesun® for the treatment of severe malaria; Eurartesim® (dihydroartemisinin-piperaquine) with Sigma-Tau; Pyramax® and Pyramax® Granules for children (pyronaridine-artesunate) co-developed with Shin Poong; and Guilin’s sulphadoxine-pyrimethamine + artesunate amodiaquine (SP+AQ) for seasonal malaria chemoprevention, which received WHO prequalification with MMV’s support. Furthermore, with MMV support, Cipla’s rectal artesunate (RAS) product was issued a 12-month authorization for procurement by the Global Fund Expert Review Panel (ERP), while regulatory/WHO prequalification review is ongoing for the same product as well as that of Strides Shasun. In addition, MMV has taken over the stewardship of two approved artemisinin combination therapies (ACTs) developed by Drugs for Neglected Diseases initiative (DNDi) and partners – artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ).
Since 2009, over 300 million courses of Coartem Dispersible treatment have been supplied to 50 malaria-endemic countries; and since prequalification in 2010, an estimated 75 million vials of artesunate injection have been delivered, saving 450,000–500,000 additional lives.
MMV and partners manage a portfolio of 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled. The portfolio includes nine new drugs in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. MMV’s success in research and access & product management comes from its 150 active global partnerships. Since its inception in 1999, MMV has built an extensive network of over 400 pharmaceutical, academic and endemic-country partners in more than 55 countries.
MMV’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.
For further information please contact:
Senior Director, Communications
Tel: +41 22 555 0327
Mob: +41 79 707 7181
email: banerjij [at] mmv.org